PTA-News: Dr. Hönle AG: Positive outlook for the Hönle Group
Business news for the stock market
Gräfelfing/München (pta002/21.08.2015/03:05) - The Hönle Group's sales revenues increased by 9.4 % to TEur 67,166 in the first nine months of the 2014/2015 financial year. At the same time, the operating result (EBIT) surged 49.1 % to TEur 9,494. Earnings before tax (EBT) climbed by 51.6 % to TEur 9.161, while the consolidated result increased by 47.8 % to TEur 6,709. This corresponds to earnings per share of Eur 1.19 (PY: Eur 0.80).
The profit ratios thus improved perceptibly when compared to the previous year: Despite a negative earnings contribution by Raesch Quarz (Germany) GmbH, the EBIT margin rose from 10.3 % to 14.1 %. Net return on sales increased from 7.4 % to 10.0 %.
The Hönle Group's business development is influenced by global economic trends. The low euro exchange rate is projected to impact positively on Hönle Group's sales development owing to the Group's high proportion of exports.
Given unchanged macro-economic conditions, the Management Board expects sales of about
Eur 90 million (previously between Eur 85 million and Eur 95 million) for the Hönle Group and an operating result of ca. Eur 13.5 million (previously between Eur 12 million and Eur 14 million) in financial year 2014/2015. The consolidated result is expected to amount to approximately Eur 10 million.
The good orders situation in the 'Equipment and Systems' segment will contribute to a positive sales and earnings development in the fourth quarter also. Promising projects in the digital printing, curing adhesives and sun simulation segments also point to favourable revenue development in the next quarters.
Management expects solid fourth quarter sales and earnings for the 'Adhesives' segment. Consumer electronics and smart cards will continue to be important fields of application for industrial adhesives of the Panacol Group. Promising projects are also being carried out in the medical technology segment. The adhesives are to be used in the manufacture of medical single-use products such as syringes.
All measures aimed at achieving the technical optimisation of melting furnaces were implemented at Raesch Quarz (Germany) GmbH, which is part of the 'Glass and Lamps' segment. The reject rates dropped significantly as a result of these restructuring measures. This lays the groundwork for the company's future success. The company provided positive earnings contributions in the third quarter as planned. Constantly rising sales revenues are expected at Raesch Quarz (Germany) GmbH over the short- to medium-term. The earnings situation is also expected to improve significantly in the coming financial year.
The complete 9-month report can be downloaded here: http://www.hoenle.de/en/ir-reports/
Dr. Hönle AG is a listed technology company with head office in Gräfelfing, near Munich. With a staff level of more than 500 employees, the Hönle Group is one of the world's leading systems suppliers in the UV technology segment. The equipment and systems are used for drying inks and coatings, curing adhesives and plastics, disinfecting surfaces, and in the simulation of natural sunlight. The company's business activities also include the development and sale of industrial adhesives and sealings. In addition, the group manufactures UV lamps that are used in water sterilisation and for other applications, and produces tubing and semi-finished goods made of quartz glass that are used by various branches of industry. The Hönle Group is represented worldwide at 69 locations in 27 countries by own companies and sales partners.
emitter: Dr. Hönle AG
address: Lochhamer Schlag 1, 82166 Gräfelfing/München
contact person: Peter Weinert
phone: +49 89 85608-173
ISIN(s): DE0005157101 (share)
stock exchanges: regulated market in Frankfurt; free market in Stuttgart, free market in Munich, free market in Hamburg, free market in Dusseldorf, free market in Hannover; open market in Berlin